Central Nervous System Drug Delivery Specialists

The blood-brain barrier (BBB) is so effective at limiting the passage of exogenous substances that many drugs with the potential to treat CNS diseases are rendered ineffective by their inability to reach their target. Consequently, companies that develop innovative delivery technologies are in a position to play a vital role in CNS drug development.

Get your copy of this report @ http://www.rnrmarketresearch.com/central-nervous-system-drug-delivery-specialists-market-report.html

Features and Benefits

• Identify the leading companies with innovative technologies designed to enhance CNS drug delivery.
• Compare the technologies that each company has developed and the diseases to which they are being applied.
• Evaluate each company’s pipeline of products and the intellectual property on which these are based.
• Assess the alliances that have been formed to maximize the opportunities for commercial exploitation of the innovations.

Highlights

Many drug delivery specialists have developed novel technology platforms to improve the passive or active transport of therapeutics across the blood-brain barrier through the encapsulation of drugs within liposomes (ArmaGen Technologies, Corden Pharma Switzerland), bolaamphiphilic vesicles (Lauren Sciences), and nanoparticles (to-BBB Technologies).

There has been success in circumventing the BBB by developing biodegradable implants (Durect Corporation) and programmable infusion devices (DePuy, Flowonix, Medtronic) for the localized delivery of drugs.

Intranasal delivery, which allows direct nose-to-brain access through the olfactory region, holds much promise. Medical device companies Kurve Technology, Impel NeuroPharma, and OptiNose have all developed devices that are compatible with intranasal delivery, and several products are now under evaluation.

Your key questions answered

• Which companies are at the cutting-edge of CNS drug delivery technology?
• How extensive are the patent portfolios supporting the company’s innovations?
• What alliances have been formed to accelerate the commercial exploitation of the delivery technologies?
• What are the prospects of success for each company’s technological innovations?

Table of Contents

EXECUTIVE SUMMARY
Key findings

Drug delivery specialists, strategic alliances, and intellectual property
Leading companies
Alkermes
Angiochem
ArmaGen Technologies
biOasis Technologies
Corden Pharma Switzerland LCC
D-Pharm
Durect Corporation
Flowonix Medical
Impel NeuroPharma
Kurve Technology
Lauren Sciences
Medtronic
OptiNose
Raptor Pharmaceutical Corporation
to-BBB Technologies BV
Conclusions 

Appendix
Scope
Methodology
Acknowledgements
Abbreviations
Bibliography/references

TABLES
Table: Innovative drug delivery specialists targeting unmet clinical need in the CNS

Report Details:

Published: Sep 2012

No. of pages:40

Price: Single User License: US $3800      Corporate User License: US $9500